- Levofloxacin hydrate
-
- $29.00 / 100mg
-
2026-03-13
- CAS:138199-71-0
- Min. Order:
- Purity: 98.56%
- Supply Ability: 10g
- Levofloxacin hydrate
-
- $29.00 / 100mg
-
2026-03-13
- CAS:138199-71-0
- Min. Order:
- Purity: 98.56%
- Supply Ability: 10g
|
| | Levofloxacin heMihydrate Basic information |
| | Levofloxacin heMihydrate Chemical Properties |
| Melting point | 214-216°C | | storage temp. | Sealed in dry,2-8°C | | solubility | Aqueous Base (Slightly), DMSO (Sparingly), Methanol (Slightly) | | form | Solid | | color | Pale Yellow to Light Yellow | | Major Application | pharmaceutical (small molecule) | | InChI | 1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1 | | InChIKey | SUIQUYDRLGGZOL-RCWTXCDDSA-N | | SMILES | O.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O.C[C@H]5COc6c(N7CCN(C)CC7)c(F)cc8C(=O)C(=CN5c68)C(O)=O | | CAS DataBase Reference | 138199-71-0(CAS DataBase Reference) |
| Hazard Codes | N | | Risk Statements | 50/53 | | Safety Statements | 24/25-61-60 | | WGK Germany | 3 | | HS Code | 2934990002 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
Resp. Sens. 1
Skin Sens. 1 |
| | Levofloxacin heMihydrate Usage And Synthesis |
| Chemical Properties | Pale Yellow Solid | | Uses | antibacterial | | Uses | Levofloxacin Hemihydrate is a S-(-) form of Ofloxacin (O245750), an antibiotic used against gram-negative organisms. | | Uses | Levofloxacin heMihydrate is an antibiotic used against gram-negative organisms. | | Brand name | Iquix (Sanofi Winthrop); Levaquin
(Ortho-McNeil); Quixin (Sanofi Winthrop). | | in vivo | Levofloxacin (10.7 mg/kg; i.p., once daily for 10 days or 3 weeks) time-dependently induces toxic effects on liver and heart in albino mice[4]. | Animal Model: | Matured male Albino mice[4] | | Dosage: | 10.7 mg/kg | | Administration: | Intraperitoneal injection; 10.7 mg/kg, once daily for 10 days or 3 weeks | | Result: | Induced severe congestion of blood vessels in the portal area, central veins with inflammatory cells infiltration, necrosis with pyknosis of cardiac muscle nuclei and apoptosis, degeneration and necrosis of hepatocytes.
|
| | IC 50 | TOPO IV |
| | Levofloxacin heMihydrate Preparation Products And Raw materials |
|